+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 0 - 12Years
All Genders
Healthy Volunteers
ID05351216

Studying Sirolimus Impact on Vaccination Safety and Immune Response in Children With Kaposiform Hemangioendothelioma up to Age 12

Led by Children's Hospital of Fudan University · Updated on 2025-06-27

174

Participants Needed

1

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating the antibody protection and immune memory after vaccination in children with Kaposiform Hemangioendothelioma KHE who are receiving sirolimus treatment. The study aims to explore the safety and effectiveness of timely vaccinations during sirolimus administration and to find alternative vaccination plans for KHE patients on sirolimus who do not respond to primary vaccinations. KHE mainly affects infants and young children under 1 year old, with a significant portion being neonates. Sirolimus suppresses the immune system, often leading to paused vaccinations and leaving children vulnerable to infections. The study addresses concerns about live vaccines causing severe infections and the loss of immune memory commonly seen in patients receiving immunosuppressive treatments.

CONDITIONS

Brief Title

The Effect of Sirolimus on Immunizations During the Treatment of Kaposiform Hemangioendothelioma

Research Team

K

Kai Li, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here